Fabian Voß

Cardiologist - Heart Failure, Heart Transplant, Cardiac Amyloidosis, Cardio-Oncology, ICU and Cardiac Arrest

[RTHahnMD @hahn_rt]

JUST PUBLISHED @JACCJournals https://t.co/tzM55bMgap See Online score https://t.co/CZ0OEbc3Sc Congrats @j_hausleiter @JennifervStein @KP_Kresoja @PhilippLurz @MariannaAdamo1 @Sticchi_Alex @JGrapsa @MarcoMetra @escardio @ACCinTouch

[Elric Zweck @ElricZweck]

New🔥 #CSWG study: 🔑 messages:
1) most changes in clinical trajectories in CS patients occur within the first 6h of admission already (#goldenshift) ⏱️
2) phenotyping and SCAI staging can be combined to improve risk stratification!🎯
https://t.co/9rBetxxrU8

[Giuseppe Galati @GiuseppeGalati_]

🔥 🔥 2 state of art 🗞️ on
📍 Non-amyloid specific
📍 Amyloid specific

Treatments of #ATTR

🔍What you can do with the 4 pillars & more
🔬 From stabilizers to siRNA & gene editing 🧬

@HFUAcademy 🫀

👉https://t.co/matDh5Q5kg
👉https://t.co/6jbJcWY41n
@ESC_Journals
@ehj_ed @EJHFEiC
@dr_pavia @MicheleEmdin @AlbertoAimo90 @IacopoOlivotto @glimongelli @DrMarthaGulati @stefanocarugo @ShelleyZieroth @scottdsolomon @DrRajivsankar @KTamirisaMD @mvaduganathan

[@SN_Oncology @SN_Oncology]

🚨Recently Published in #CardioOncology

Evaluation of a screening algorithm to detect cardiac amyloidosis in mild to severe aortic valve stenosis🫀

#OpenAccess

Read more➡️https://t.co/2LJaoxC6OJ @vofab @ICOSociety

[Amin Polzin @amin_polzin]

#Wire-Based Interventional Clip Excision (WICE Procedure) to Allow Tran... https://t.co/B6edw2eb46
🔍 New #treatment approach for recurrent tricuspid regurgitation after #TEER!
#TricuspidValve #TTVR #StructuralHeart #InterventionalCardiology #CardiologyResearch #AgPolzin

[J.G. Córdoba @JGCorSo]

In this multicenter European registry, those patients in mid stage but not those in early or late stage of Tricuspid Regurgitation disease, showed significant 1-year survival with #TTEER vs conservative management. 4-parameter easy score to identify them. Thanks to the authors.

[Elric Zweck @ElricZweck]

I’m honored to soon be serving on the steering committee of the CSWG alongside my fellow #cardiogenic #shock warriors, following the vision and leadership of @NavinKapur4 @BurkhoffMd @manreetkanwar @JHMontfort10 @ShashankSinhaMD and @ReshadGaranMD

[NEJM @NEJM]

Presented at #AHA24:

In patients with heart failure with preserved ejection fraction and obesity, treatment with tirzepatide led to a lower risk of death from cardiovascular causes or worsening heart-failure events than placebo. Full trial results: https://t.co/ib0n1GaRtR

[ESC Heart Failure Journal @ESCHeartFailure]

🫀#RealWorldData on cardiac #amyloidosis treatment!

64% of #ATTRCM patients meet tafamidis trial criteria with treated patients showing higher #survival rates. High need for early detection🔥

Online: https://t.co/4kElXBDqCo

@PiotrPonikowski #ATTR #HeartFailure #CardioTwitter

[NEJM @NEJM]

Original Article: Transcatheter Valve Replacement in Severe Tricuspid Regurgitation (TRISCEND II) https://t.co/lcXsj8TLvU

Editorial: Early-Stage Results with Transcatheter Tricuspid-Valve Replacement https://t.co/YH63OQqUsG

#TCT2024 | @crfheart

[Saraschandra Vallabhajosyula, MD MSc @SarasVallabhMD]

Congratulations to @ElricZweck, #JacobMoller and team for their late breaking work on #AKI in #AMICS at #TCT2024 with a simultaneous publication in @CircAHA - https://t.co/jR0HR9AENo. I had the privilege of writing the editorial comment https://t.co/jR0HR9AENo. @BrownUnivHealth

[Ronald Witteles @Ron_Witteles]

🚨­­ MAJOR news in the #ATTR #amyloidosis world! Today the ­­­much-anticipated HELIOS-B results were presented @escardio & simultaneously published in @NEJM. The largest ATTR-CM trial published to date, testing #vutrisiran vs. placebo. Bottom line: Huge win for vutrisiran! Lowered CV events and All-Cause mortality in the overall population & as monotherapy. Now, let’s take a deep dive into the results… https://t.co/iCeK5liS2M

[Eric H Yang, MD @datsunian]

A herculean #cardioonc effort amongst experts in assembling this statement on the rapidly evolving landscape of CV toxicities in cancer immunotherapeutics.

Great resource to study more of what we don't know!

👏to colleagues and friends

@ESC_Journals
https://t.co/x0xSJ57hmw

[Fabian Voß @vofab]

Thanks for sharing our latest publication @SN_Oncology and even more to the whole Team and all participating patients!

@florian_bonner @RalfWestenfeld @cjungMD @DanielScheiber @SM_Haberkorn @amin_polzin

[@SN_Oncology @SN_Oncology]

Anthracycline therapy induces an early decline of systolic mayocardial function even among young breast cancer patients without known cardiovascular risk factor @vofab @florian_bonner @RalfWestenfeld @DanielScheiber @cjungMD @amin_polzin @UniklinikDUS https://t.co/HcZpoevyXo

[Gregg W. Stone MD @GreggWStone]

1/2 Following the DANGER SHOCK trial demonstrating reduced mortality with Impella in cardiogenic shock, the independent DSMB of the RECOVER IV trial has strongly recommended the trial be discontinued because of lack of equipoise. Therefore, we are ceasing enrollment in the trial.

[Amin Polzin @amin_polzin]

We are proud to announce that the cardiology team at @UniklinikDUS successfully performed the first interventional transfemoral tricuspid valve replacement this week! A huge thank you to the entire team!

[Janine Pöss @JaninePoss]

💥Happy to share publication of pilot phase of our German Cardiac Arrest Registry (G-CAR):
https://t.co/VR0bqdvDR0

➡️ next step: assessment of PROs
🙏 Thanks to all the investigators!
#CardiacArrest #OHCA
@DGK_AG3 @AnneFreund3 @thiele_holger @jochen_dutzmann @EPTIG

[Edgardo Alania @Ed_Alania]

🔴 SGLT2 Inhibitor Therapy in Patients With TTR Amyloid Cardiomyopathy @JACCJournals #CardioEd #Cardiology #FOAMed #Amyloidosis

[Fabian Voß @vofab]

Happy to share our latest article discussing mitochondrias oxidative capacity in different subtypes of cardiac amyloidosis published by @JACCJournals !

@DanielScheiber @ElricZweck @RalfWestenfeld @amin_polzin

[Elric Zweck @ElricZweck]

New 🔥 article from our Düsseldorf lab, just published in @JACCJournals Heart Failure:
Cardiac light-chain vs. transthyretin #amyloidosis have distinct mitochondrial characteristics @vofab @DanielScheiber @RalfWestenfeld @amin_polzin @DGK_org @BiykemB
https://t.co/Oot5UcwOF2

[Fabian Voß @vofab]

@ElricZweck @HarvardChanSPH @RalfWestenfeld @NavinKapur4 @MarcDonath Congrats! Well deserved!